Last reviewed · How we verify

NCT05827471

Clinical Study of QSOX1 as a Biomarker for Colon Cancer

Not yet recruiting Last updated 25 April 2023
What this trial tests

trial testing Diagnosis of colon cancer in Colon Cancer in 400 participants. Not yet recruiting.

Timeline
1 July 2023
Primary endpoint
30 June 2026
31 December 2026

Quick facts

Lead sponsorQianfoshan Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment400
Start date1 July 2023
Primary completion30 June 2026
Estimated completion31 December 2026

Drugs / interventions tested

Conditions studied

Sponsor

Qianfoshan Hospital

Who can join

Adults 18 to 80, any sex, with Colon Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to determine whether the secreted protein QSOX1 can be used as a molecular marker for early rapid diagnosis and accurate treatment of colon cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Colon Cancer

Currently open trials in the same condition.

Other Qianfoshan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05827471.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing